Last reviewed · How we verify
LY2062430
LY2062430 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain.
LY2062430 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain. Used for Huntington's disease.
At a glance
| Generic name | LY2062430 |
|---|---|
| Also known as | A Beta Antibody, Solanezumab (*USAN adopted name, INN pending) |
| Sponsor | Eli Lilly and Company |
| Drug class | PDE10A inhibitor |
| Target | PDE10A (Phosphodiesterase 10A) |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | Phase 3 |
Mechanism of action
PDE10A is an enzyme highly expressed in the striatum and other brain regions involved in motor control and cognition. By inhibiting PDE10A, the drug increases levels of cyclic nucleotides (cAMP and cGMP), which modulate neuronal activity and may restore balance in dysregulated neural circuits. This mechanism has been explored for neuropsychiatric and neurodegenerative disorders.
Approved indications
- Huntington's disease
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
Key clinical trials
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (PHASE2, PHASE3)
- Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (PHASE3)
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (PHASE2, PHASE3)
- A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) (PHASE1)
- A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease (PHASE3)
- Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo (PHASE3)
- Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease (PHASE3)
- Effect of LY2062430 on the Progression of Alzheimer's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2062430 CI brief — competitive landscape report
- LY2062430 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI